CY1118151T1 - Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη - Google Patents
Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινηInfo
- Publication number
- CY1118151T1 CY1118151T1 CY20161100934T CY161100934T CY1118151T1 CY 1118151 T1 CY1118151 T1 CY 1118151T1 CY 20161100934 T CY20161100934 T CY 20161100934T CY 161100934 T CY161100934 T CY 161100934T CY 1118151 T1 CY1118151 T1 CY 1118151T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amyloidoidism
- inhibitor
- new transmission
- comt
- transmission treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| EP12778323.1A EP2770988B1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118151T1 true CY1118151T1 (el) | 2017-06-28 |
Family
ID=47076222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100934T CY1118151T1 (el) | 2011-10-24 | 2016-09-20 | Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (https=) |
| EP (1) | EP2770988B1 (https=) |
| JP (1) | JP6068484B2 (https=) |
| KR (1) | KR102017354B1 (https=) |
| CN (1) | CN103889407B (https=) |
| AU (2) | AU2012327275B2 (https=) |
| BR (1) | BR112014009322B1 (https=) |
| CA (1) | CA2852808C (https=) |
| CL (1) | CL2014000893A1 (https=) |
| CY (1) | CY1118151T1 (https=) |
| ES (1) | ES2593038T3 (https=) |
| IL (1) | IL231907B (https=) |
| MX (2) | MX347784B (https=) |
| PL (1) | PL2770988T3 (https=) |
| PT (1) | PT2770988T (https=) |
| RU (2) | RU2747536C2 (https=) |
| SG (2) | SG11201401215VA (https=) |
| WO (1) | WO2013060668A1 (https=) |
| ZA (1) | ZA201402546B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
| CN113599539A (zh) * | 2014-08-29 | 2021-11-05 | 阿尔尼拉姆医药品有限公司 | 治疗甲状腺素运载蛋白（ttr）介导的淀粉样变性的方法 |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| AU2019236469A1 (en) * | 2018-03-12 | 2020-10-08 | Corino Therapeutics, Inc. | Combination therapy for TTR amyloidosis |
| CA3141998A1 (en) * | 2019-05-31 | 2020-12-03 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating protein aggregation diseases of the eye |
| EP4243798A4 (en) * | 2020-11-13 | 2024-08-21 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
| JP2025536853A (ja) * | 2022-10-10 | 2025-11-07 | コリノ セラピューティクス，インク． | 放出調節トルカポン処方剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
| FI20002044A0 (fi) * | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| EP1372682B1 (en) | 2001-03-15 | 2012-05-02 | Proteotech Inc. | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| WO2003063880A1 (en) | 2002-01-29 | 2003-08-07 | Protemix Corporation Limited | Disruption of islet amyloid by polycyclic compounds |
| US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| WO2005113523A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| DE602005019582D1 (de) | 2004-08-30 | 2010-04-08 | Seo Hong Yoo | Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
-
2012
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh not_active Expired - Fee Related
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active Active
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en not_active Ceased
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en not_active Ceased
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 MX MX2017006182A patent/MX385516B/es unknown
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en not_active Ceased
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118151T1 (el) | Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1121379T1 (el) | Πολυθεραπεια για την ισχαιμια | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CY1120506T1 (el) | Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων | |
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CY1120374T1 (el) | Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια | |
| CR9882A (es) | Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2019010422A (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. | |
| CR20150571A (es) | Compuestos y composiciones terapéuticos | |
| CL2015002807A1 (es) | Terapia de combinación | |
| MX2020003174A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
| MX373925B (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| CL2015002534A1 (es) | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada |